An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232-104 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)

Shortt, Jake (Primary Chief Investigator (PCI))

Medicine Monash Health

Project: Research

Project Description

NMA HREC Reference Number: 65293
NMA SSA Reference Number: SSA/65293/MonH-2020-234837(v2)
Monash Health Reference: RES-20-0000-433A

Status	Finished
Effective start/end date	8/09/20 → 7/09/25

Keywords

clinical trial
phase 1 and 2 study
treatment safety
treatment efficacy
leukemia

Clinical Trial Phase

Phase I
Phase II